780 related articles for article (PubMed ID: 28291719)
1. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa.
Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM
J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719
[TBL] [Abstract][Full Text] [Related]
2. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.
Weimer ET; Lu H; Kock ND; Wozniak DJ; Mizel SB
Infect Immun; 2009 Jun; 77(6):2356-66. PubMed ID: 19349426
[TBL] [Abstract][Full Text] [Related]
3. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
Weimer ET; Ervin SE; Wozniak DJ; Mizel SB
Vaccine; 2009 Nov; 27(48):6762-9. PubMed ID: 19744586
[TBL] [Abstract][Full Text] [Related]
4. [Production of hybrid protein OprF-OprL of Pseudomonas aeruginosa].
Kaloshin AA; Mikhaĭlova NA; Leonova EI
Zh Mikrobiol Epidemiol Immunobiol; 2012; (3):35-43. PubMed ID: 22830272
[TBL] [Abstract][Full Text] [Related]
5. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa.
Zhang M; Sun C; Gu J; Yan X; Wang B; Cui Z; Sun X; Tong C; Feng X; Lei L; Han W
Microbiol Immunol; 2015 Sep; 59(9):533-44. PubMed ID: 26249788
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
Westritschnig K; Hochreiter R; Wallner G; Firbas C; Schwameis M; Jilma B
Hum Vaccin Immunother; 2014; 10(1):170-83. PubMed ID: 24064511
[TBL] [Abstract][Full Text] [Related]
7. [Construction of recombinant Bb(pGEX-OprF-I) vaccine of Pseudomonas aeruginosa and its protection elicited in mice].
Liang C; Li W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Jul; 35(7):589-594. PubMed ID: 31537242
[TBL] [Abstract][Full Text] [Related]
8. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients.
Mansouri E; Blome-Eberwein S; Gabelsberger J; Germann G; von Specht BU
FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):161-6. PubMed ID: 12832120
[TBL] [Abstract][Full Text] [Related]
9. Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.
Cui Z; Han D; Sun X; Zhang M; Feng X; Sun C; Gu J; Tong C; Lei L; Han W
Appl Microbiol Biotechnol; 2015 Jan; 99(2):667-80. PubMed ID: 25381907
[TBL] [Abstract][Full Text] [Related]
10. [Study on Construction of Recombinant Bb-pGEX-
Liu X; Li WG; Luo GX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):13-17. PubMed ID: 29737082
[TBL] [Abstract][Full Text] [Related]
11. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.
Baumann U; Göcke K; Gewecke B; Freihorst J; von Specht BU
Respir Res; 2007 Aug; 8(1):57. PubMed ID: 17683588
[TBL] [Abstract][Full Text] [Related]
12. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
von Specht B; Knapp B; Hungerer K; Lücking C; Schmitt A; Domdey H
J Biotechnol; 1996 Jan; 44(1-3):145-53. PubMed ID: 8717398
[TBL] [Abstract][Full Text] [Related]
13. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
[TBL] [Abstract][Full Text] [Related]
14. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa.
Arnold H; Bumann D; Felies M; Gewecke B; Sörensen M; Gessner JE; Freihorst J; von Specht BU; Baumann U
Infect Immun; 2004 Nov; 72(11):6546-53. PubMed ID: 15501786
[TBL] [Abstract][Full Text] [Related]
15. A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa.
Knapp B; Hundt E; Lenz U; Hungerer KD; Gabelsberger J; Domdey H; Mansouri E; Li Y; von Specht BU
Vaccine; 1999 Mar; 17(13-14):1663-6. PubMed ID: 10194820
[TBL] [Abstract][Full Text] [Related]
16. Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous
Liu C; Pan X; Xia B; Chen F; Jin Y; Bai F; Priebe G; Cheng Z; Jin S; Wu W
Front Immunol; 2018; 9():1737. PubMed ID: 30093906
[No Abstract] [Full Text] [Related]
17. Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection.
Farajnia S; Peerayeh SN; Tanomand A; Majidi J; Goudarzi G; Naghili B; Rahbarnia L
Can J Microbiol; 2015 Jan; 61(1):60-4. PubMed ID: 25496361
[TBL] [Abstract][Full Text] [Related]
18. Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers.
Bumann D; Behre C; Behre K; Herz S; Gewecke B; Gessner JE; von Specht BU; Baumann U
Vaccine; 2010 Jan; 28(3):707-13. PubMed ID: 19887136
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.
Mansouri E; Gabelsberger J; Knapp B; Hundt E; Lenz U; Hungerer KD; Gilleland HE; Staczek J; Domdey H; von Specht BU
Infect Immun; 1999 Mar; 67(3):1461-70. PubMed ID: 10024596
[TBL] [Abstract][Full Text] [Related]
20. Immunization with Bivalent Flagellin Protects Mice against Fatal
Behrouz B; Hashemi FB; Fatemi MJ; Naghavi S; Irajian G; Halabian R; Imani Fooladi AA
J Immunol Res; 2017; 2017():5689709. PubMed ID: 29201922
[No Abstract] [Full Text] [Related]
[Next] [New Search]
